Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial Meeting Abstract

  

Authors:	Balar, A. V.; Milowsky, M. I.; O'Donnell, P. H.; Alva, A. S.; Kollmeier, M.; Rose, T. L.; Pitroda, S.; Kaffenberger, S. D.; Rosenberg, J. E.; Francese, K.; Hochman, T.; Goldberg, J. D.; Griglun, S.; Leis, D.; Steinberg, G. D.; Wysock, J.; Schiff, P. B.; Sanfilippo, N. J.; Taneja, S.; Huang, W. C.
Abstract Title:	Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial
Meeting Title:	2021 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	39
Issue:	15 Suppl.
Meeting Dates:	2021 Jun 4-8
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2021-05-20
Language:	English
ACCESSION:	WOS:000708120602253
DOI:	10.1200/JCO.2021.39.15_suppl.4504
PROVIDER:	wos
Notes:	Meeting Abstract: 4504 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/191251